A US-based KOL provides insights into the treatment pathway of HR+/HER2- breast cancer with a focus on the sequential use of CDK4/6 inhibitors in metastatic disease and choosing the optimal drugs in later lines of therapy. The KOL also highlights the promise of next-generation endocrine therapies and the potential of vaccine technologies. 

This interview was conducted on Aug. 30, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.